This week, we’re sharing the most recent top stories in ophthalmology news. A new study finds people who consume alcohol moderately appear less likely to develop cataracts that require surgery.
Bausch and Lomb received FDA approval for a new viscosurgical device for ophthalmic surgery, while Johnson and Johnson received FDA clearance for a new surgical device that provides enhanced usability during cataract surgery.
Meanwhile, a recent NYU Langone study has shown a chemical that is known to protect nerve cells has also slowed the progression of glaucoma in rats.
Read more on these stories below:
Wine consumption may prevent cataracts, study finds Ophthalmology Times, April 05, 2021
Drinking alcohol on a regular basis may decrease patients’ chances of developing cataracts that require surgery, new research shows.
FDA approves Bausch + Lomb’s ClearVisc OVD Healio, April 07, 2021
Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery, according to a press release.
Johnson & Johnson Vision receives FDA clearance, CE mark for Veritas phaco system Healio, April 01, 2021
Johnson & Johnson Vision has received FDA 510(k) clearance and a CE mark for its Veritas vision system, according to a press release. The phacoemulsification system includes “technologies that allow surgeons to guide through any lens density with less surge and more stability,” the release said.
Citicoline Protects Against Glaucoma Without Reducing Fluid Pressure in Eye NYU Langone, April 14, 2021
A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show.
Johnson & Johnson Vision Introduces Acuvue Abiliti to Address Myopia in Children Eyewire, April 21, 2021
Johnson & Johnson Vision announced the launch of Acuvue Abiliti, a new brand for future products and services aimed at helping parents and eye care providers address the growing prevalence and progression of myopia in children.